These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11496831)

  • 1. Protease inhibitors, part 13: Specific, weakly basic thrombin inhibitors incorporating sulfonyl dicyandiamide moieties in their structure.
    Clare BW; Scozzafava A; Supuran CT
    J Enzyme Inhib; 2001 Jan; 16(1):1-13. PubMed ID: 11496831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1.
    Supuran CT; Scozzafava A; Briganti F; Clare BW
    J Med Chem; 2000 May; 43(9):1793-806. PubMed ID: 10794696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease inhibitors. Part 2. Weakly basic thrombin inhibitors incorporating sulfonyl-aminoguanidine moieties as S1 anchoring groups: synthesis and structure-activity correlations.
    Clare BW; Scozzafava A; Briganti F; Iorga B; Supuran CT
    J Enzyme Inhib; 2000; 15(3):235-64. PubMed ID: 10811030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease inhibitors: Part 4. Synthesis of weakly basic thrombin inhibitors incorporating pyridinium-sulfanilylaminoguanidine moieties.
    Supuran CT; Briganti F; Scozzafava A; Ilies MA
    J Enzyme Inhib; 2000; 15(4):335-56. PubMed ID: 10995066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies.
    De Simone G; Menchise V; Omaggio S; Pedone C; Scozzafava A; Supuran CT
    Biochemistry; 2003 Aug; 42(30):9013-21. PubMed ID: 12885234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel thrombin inhibitors incorporating weakly basic heterobicyclic P1-arginine mimetics: optimization via modification of P1 and P3 moieties.
    Kranjc A; Peterlin-Masic L; Ilas J; Prezelj A; Stegnar M; Kikelj D
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3251-6. PubMed ID: 15149685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease inhibitors - Part 3. Synthesis of non-basic thrombin inhibitors incorporating pyridinium-sulfanilylguanidine moieties at the P1 site.
    Scozzafava A; Briganti F; Supuran CT
    Eur J Med Chem; 1999 Nov; 34(11):939-952. PubMed ID: 10889318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.
    Sielaff F; Böttcher-Friebertshäuser E; Meyer D; Saupe SM; Volk IM; Garten W; Steinmetzer T
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4860-4. PubMed ID: 21741839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine.
    Reers M; Koschinsky R; Dickneite G; Hoffmann D; Czech J; Stüber W
    J Enzyme Inhib; 1995; 9(1):61-72. PubMed ID: 8568567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.
    Tucker TJ; Lumma WC; Mulichak AM; Chen Z; Naylor-Olsen AM; Lewis SD; Lucas R; Freidinger RM; Kuo LC
    J Med Chem; 1997 Mar; 40(6):830-2. PubMed ID: 9083470
    [No Abstract]   [Full Text] [Related]  

  • 12. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amidinohydrazones as guanidine bioisosteres: application to a new class of potent, selective and orally bioavailable, non-amide-based small-molecule thrombin inhibitors.
    Soll RM; Lu T; Tomczuk B; Illig CR; Fedde C; Eisennagel S; Bone R; Murphy L; Spurlino J; Salemme FR
    Bioorg Med Chem Lett; 2000 Jan; 10(1):1-4. PubMed ID: 10636229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent bicyclic lactam inhibitors of thrombin: Part I: P3 modifications.
    St-Denis Y; Augelli-Szafran CE; Bachand B; Berryman KA; DiMaio J; Doherty AM; Edmunds JJ; Leblond L; Lévesque S; Narasimhan LS; Penvose-Yi JR; Rubin JR; Tarazi M; Winocour PD; Siddiqui MA
    Bioorg Med Chem Lett; 1998 Nov; 8(22):3193-8. PubMed ID: 9873701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
    Das J; Kimball SD; Hall SE; Han WC; Iwanowicz E; Lin J; Moquin RV; Reid JA; Sack JS; Malley MF; Chang CY; Chong S; Wang-Iverson DB; Roberts DG; Seiler SM; Schumacher WA; Ogletree ML
    Bioorg Med Chem Lett; 2002 Jan; 12(1):45-9. PubMed ID: 11738570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biochemical evaluation of triazole/tetrazole-containing sulfonamides against thrombin and related serine proteases.
    Siles R; Kawasaki Y; Ross P; Freire E
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5305-9. PubMed ID: 21807511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
    Das J; Kimball SD; Reid JA; Wang TC; Lau WF; Roberts DG; Seiler SM; Schumacher WA; Ogletree ML
    Bioorg Med Chem Lett; 2002 Jan; 12(1):41-4. PubMed ID: 11738569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly selective tripeptide thrombin inhibitors.
    Shuman RT; Rothenberger RB; Campbell CS; Smith GF; Gifford-Moore DS; Gesellchen PD
    J Med Chem; 1993 Feb; 36(3):314-9. PubMed ID: 8426361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of selective boron-containing thrombin inhibitors.
    Wienand A; Ehrhardt C; Metternich R; Tapparelli C
    Bioorg Med Chem; 1999 Jul; 7(7):1295-307. PubMed ID: 10465405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and selective bicyclic lactam inhibitors of thrombin: Part 2: P1 modifications.
    Plummer JS; Berryman KA; Cai C; Cody WL; DiMaio J; Doherty AM; Edmunds JJ; He JX; Holland DR; Levesque S; Kent DR; Narasimhan LS; Rubin JR; Rapundalo ST; Siddiqui MA; Susser AJ; St-Denis Y; Winocour PD
    Bioorg Med Chem Lett; 1998 Dec; 8(23):3409-14. PubMed ID: 9873743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.